Search Results

You are looking at 71 - 80 of 286 items for :

  • "risk assessment" x
  • Refine by Access: All x
Clear All
Full access

for Key Contributions to Guidelines Program; Recognizes Meetings Department Director With Staff Award NCCN announced Mary B. Daly, MD, PhD—professor in the Department of Clinical Genetics and director of the Risk Assessment Program at Fox Chase

Full access

Mary E. Freivogel and Stephanie A. Cohen

non-genetics healthcare providers to educate and support them as they offer risk assessment and genetic testing. NSGC is not only evaluating the implementation of traditional and novel service delivery models, but also examining outcomes measures to

Full access

Judith A. Paice

families about risks and appropriate use of opioids; better education of oncology professionals about comprehensive pain and risk assessment, tolerance, universal precautions, and regulations to guide clinical practice; and better access to data, counseling

Full access

Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa

published article, modifying thrombosis risk is paramount in the management of ET and PV. 1 Formal guidelines for hematologists and hematologist-oncologists could provide a consensus-based vascular risk assessment and suggest appropriate clinical

Full access

consideration of risk assessment. (This recommendation also applies to other pages.) Footnote “f” was modified, “Observation may be considered, with the understanding that there is significantly greater incidence of adverse outcomes (residual disease

Full access

Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes

those who are initially unresectable, or those with bilateral or metastatic disease. Risk assessment is done to determine the need for and type of adjuvant therapy after surgery (see Risk Assessment for FHWT [WILMS-F] in the algorithm). 10 , 64 Most

Full access

Tarra Evans and Ursula Matulonis

Clinical Implications Genetic Risk Assessment During the past decade, NGS panels of genes associated with gynecologic malignancies have become important tools in counseling patients and families concerning cancer risk, risk-reduction planning, and

Full access

Suzanne M. Mahon

implications of incomplete family history include inaccurate or incomplete risk assessment, which may result in inappropriate testing or failure to identify at-risk relatives who may also need testing. 4 If family members with mutations are not identified

Full access

Gayathri Nagaraj and Cynthia X. Ma

Predictive Biomarkers in Early-Stage Breast Cancer MammaPrint MammaPrint is a microarray-based multigene assay designed for risk assessment in patients with node-negative breast cancer regardless of ER status. The 70-gene signature consists of

Full access

Rafael Bejar

. Additional mutations will accumulate, often leading to a more profound phenotype of worsening cytopenias, and approximately 30% of patients will eventually experience progression to secondary AML.” Personalized Risk Assessment Using a case study involving a